Lorna Graham of Worldwide Clinical Trials to Present at Evidence USA 2016
MORRISVILLE, North Carolina, October 17, 2016 /PRNewswire/ --
Lorna Graham, Associate Director of Project Management for Worldwide Clinical Trials (http://www.worldwide.com), will present at Evidence USA 2016, which is being held at the Hilton Philadelphia City Avenue in Philadelphia, PA, Oct. 18-19, 2016. Graham's session is titled: "Is Technology the Key to Naturalistic Observational Research?"
During her presentation, Graham will focus on technology's impact on standards of care, home health care, and real-world outcomes research. She will also discuss how "Big Data" and data mining can aid in scenario computations; help reduce biases in studies; and deliver intelligence to support patient retention. Graham's session will take place on Tuesday, Oct. 18 at 4:25 pm ET.
"During my presentation, we'll take a look at how technology is having a major impact on the design and execution of clinical research programs," said Graham. "The industry is becoming more and more interested in how technology and Big Data can impact the development and adoption of universal health standards, driving a greater need for the delivery of long-term health evidence and justification of healthcare costs."
Evidence USA is America's largest and most comprehensive event on the use of real world outcomes for pharmaceutical products. The event features an exhibition and a multi-track strategic conference.
Connect with Worldwide Clinical Trials:
- Tweet: @worldwidetrials to present at Evidence USA 2016
- Follow us on Twitter: @worldwidetrials
- Find us on LinkedIn: https://www.linkedin.com/company/worldwide-clinical-trials-inc-
About Worldwide Clinical Trials
Worldwide Clinical Trials employs more than 1,400 professionals around the world, with offices in North and South America, Eastern and Western Europe, Russia and Asia. One of the world's leading, full-service contract research organizations (CROs), we partner with sponsors in the pharmaceutical and biotechnology industries to deliver fully integrated clinical development and bioanalytical services, extending from first-in-human through phase IV studies. Grounded in medicine and science, we help sponsors move from medical discovery into clinical development and commercialization across a range of therapeutic areas, including neuroscience, cardiovascular diseases, immune-mediated inflammatory disorders (IMID), and rare diseases. For more information, visit http://www.worldwide.com.
SOURCE Worldwide Clinical Trials